In ten years, the growth of the stem cell market (estimated at + 11.7 %/year worldwide) has promoted the clinical development of cell therapies in regenerative medicine (heart failure,...) or immunotherapy (cancer,...). According to European regulations 1394/2007, these cellular products have a medicinal status (Innovative Therapy Medicines, MTI) and must be prepared according to Good Manufacturing Practices (GMP). Academic structures, due to their privileged links with clinicians, occupy a prominent place in this very promising field of ITMs. The university hospitals in Nancy and Strasbourg have affirmed their expertise in specific and complementary areas: Nancy in clinical research in cell engineering and Strasbourg in innovative medical devices (DMI) in tissue engineering. The main objective of this project is to implement clinical trials with ITMs and MIDs in accordance with European regulations. Thus, the emergence of two platforms, equipped, in the Grand Est (GE) region — one pharmaceutical for experimental MTIs in Nancy, and the other for DMI in Strasbourg, both collaborating for MTIs combining cells and DMI — is carried by the CHUs and universities in the GE region, as well as by ARS-GE. This structuring will position the GE region as a key player in these areas, at national and European level.